These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 486317)

  • 1. Fc receptor-bearing and phagocytic cells in syngeneic tumours of C. parvum- and carrageenan-treated mice.
    Thomson AW; Cruickshank N; Fowler EF
    Br J Cancer; 1979 May; 39(5):598-602. PubMed ID: 486317
    [No Abstract]   [Full Text] [Related]  

  • 2. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of the incidence of death with spontaneous tumours in DBA/2 mice after Corynebacterium parvum-mediated rejection of syngeneic tumours.
    Likhite VV
    Nature; 1976 Feb; 259(5542):397-9. PubMed ID: 1250378
    [No Abstract]   [Full Text] [Related]  

  • 5. Study of the mechanism of Corynebacterium parvum anti-tumour activity. I. Protective effect on the growth of two syngeneic tumours.
    Mazurek C; Chalvet H; Stiffel CL; Biozzi G
    Int J Cancer; 1976 Apr; 17(4):511-7. PubMed ID: 946965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of killed Corynebacterium parvum suspensions in a murine mammary adenocarcinoma CaD2) system.
    Purnell DM; Otterstrom JR; Bartlett GL; Kreider JW
    J Natl Cancer Inst; 1976 Jun; 56(6):1171-5. PubMed ID: 994219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of C. parvum on intratumor immunity to the T1699 mammary adenocarcinoma.
    Haskill S; Ritter F; Becker S
    J Immunol; 1980 Jul; 125(1):454-8. PubMed ID: 6247400
    [No Abstract]   [Full Text] [Related]  

  • 8. Active experimental inhibition of cancer by corynebacterium parvum.
    Wrba H; Dutter A
    Osterr Z Onkol; 1977 Oct; 4(2-3):60-1. PubMed ID: 579449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rejection of mammary adenocarcinoma cell tumors in DBA/2 mice immunocompromised by thymectomy and treatment with antithymocyte serum.
    Likhite VV
    J Immunol; 1975 Jun; 114(6):1736-42. PubMed ID: 1092759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies with a spontaneous mouse tumor. I. Growth in normal mice and response to Corynebacterium parvum.
    Woodruff MF; Whitehead VL; Speedy G
    Br J Cancer; 1978 Mar; 37(3):345-55. PubMed ID: 638014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further observations on the inhibition of tumor growth by Corynebacterium parvum with cyclophosphamide. IX. Macrophage content of tumors in mice.
    Gebhardt MC; Fisher B
    J Natl Cancer Inst; 1979 Apr; 62(4):1035-41. PubMed ID: 285276
    [No Abstract]   [Full Text] [Related]  

  • 12. Enhanced Fc receptor expression by a sub-population of murine intra-tumour macrophages following intravenous Corynebacterium parvum therapy.
    Moore K; McBride WH
    Br J Cancer; 1983 Jun; 47(6):797-802. PubMed ID: 6860547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined radiotherapy and Corynebacterium parvum treatment of rat tumors with different immunogenicity.
    Moroson H; Stowe S; Rotman M; Schechter M
    Int J Radiat Oncol Biol Phys; 1978; 4(7-8):649-55. PubMed ID: 711536
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antitumor effect of Corynebacterium parvum].
    Mazurek C; Chalvet H; Biozzi G; Stiffel C
    Ann Immunol (Paris); 1977; 128(1-2):161-3. PubMed ID: 576780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C. parvum treatment of transplanted rat tumours of spontaneous origin.
    Willmott N; Pimm MV; Baldwin RW
    Int J Cancer; 1979 Sep; 24(3):323-8. PubMed ID: 385514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation therapy and Corynebacterium parvum in the treatment of murine tumors.
    Suit HD; Sedlacek RS; Silobrcic V; Linggood RM
    Cancer; 1976 Jun; 37(6):2573-9. PubMed ID: 949676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of serial transplantation on the immunological-clinical correlates of BALB/cfC3H mouse mammary tumors.
    Hager JC; Miller FR; Heppner GH
    Cancer Res; 1978 Aug; 38(8):2492-500. PubMed ID: 667845
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy of an established rat mammary adenocarcinoma (13762A) with intratumor injection of Corynebacterium parvum.
    Kreider JW; Bartlett GL; Purnell DM; Webb S
    Cancer Res; 1978 Mar; 38(3):689-92. PubMed ID: 626972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rejection of tumors and metastases in Fischer 344 rats following intratumor administration of killed Corynebacterium parvum.
    Likhite VV
    Int J Cancer; 1974 Nov; 14(5):684-90. PubMed ID: 4459281
    [No Abstract]   [Full Text] [Related]  

  • 20. Influence of immunotherapeutic agents on the progression of spontaneously arising, metastasizing rat mammary adenocarcinomas of varying immunogenicities.
    Greager JA; Baldwin RW
    Cancer Res; 1978 Jan; 38(1):69-73. PubMed ID: 618584
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.